Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
18 Abril 2024 - 7:00AM
Business Wire
Company to host conference call at 4:30 p.m.
ET
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it will issue
its financial results for the fiscal 2024 second quarter ended
March 31, 2024, after market close on Thursday, May 2, 2024. The
company plans to hold a conference call and live audio webcast for
analysts and investors at 4:30 p.m. Eastern Time to discuss its
financial results and provide an update on the company’s business.
The press release with the financial results will be accessible
from the company’s website prior to the conference call through the
Investor Relations section under the “Company” tab at
www.twistbioscience.com.
The conference call will be webcast live through the Investor
Relations section under the “Company” tab at
www.twistbioscience.com. Those parties interested in participating
via telephone must register on the Company’s Investor Relations
website or by clicking here. Upon registration, all telephone
participants will receive the dial-in number along with a unique
PIN number that can be used to access the call. To avoid delays, we
encourage participants to dial into the conference call fifteen
minutes ahead of the scheduled start time. The webcast replay will
be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418556121/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De May 2023 a May 2024